BioMaxima

BioMaxima Stock-Based Compensation

Stock-Based Compensation (SBC) of BioMaxima (BMX.WA) as of Oct 17, 2026.

Stock-Based Compensation

0.00PLN

Last updated:

Stock-Based Compensation (SBC) of BioMaxima is 2023 0.00 PLN. Stock-Based Compensation (SBC) of BioMaxima was 2022 0.00 PLN. It decreases by % lower compared to the previous year.

The BioMaxima Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
182,000.00 PLN
Jan 1, 2021
133,000.00 PLN
Jan 1, 2022
0.00 PLN
Jan 1, 2023
0.00 PLN
The BioMaxima Stock-Based Compensation history
YEARStock-Based CompensationYoY
0.00PLN—
0.00PLN-100.00%
133,000.00PLN-26.92%
182,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) BioMaxima since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s BioMaxima historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — BioMaxima

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — BioMaxima